Evaluating Clinical Practice of Early Access Avacopan Treatment for ANCA-associated Vasculitis in European Countries

What this Trial Is About

This research aims to analyze how avacopan is used early in the treatment of patients with ANCA-associated vasculitis (AAV) across Europe. It focuses on describing patient characteristics, the reasons doctors start avacopan, the treatment strategies combined with avacopan, and the clinical outcomes in a unique group of first-time avacopan users. By studying real-world use, the project hopes to identify important issues in applying avacopan in daily practice and to fill knowledge gaps to improve care and drug access for AAV patients. The study observes patients who have started avacopan treatment for AAV without assigning specific treatments or interventions. Data about the patients' clinical features, treatment choices, and responses are collected through questionnaires over one to two years. The study looks at how doctors decide to start avacopan, the combination of immunosuppressive treatments used, and the clinical benefits measured by the Birmingham Vasculitis Activity Score (BVAS). Researchers also investigate factors that may predict non-response or relapse during avacopan treatment. Participants provide informed consent to share their medical data, which is gathered and analyzed to understand treatment patterns and outcomes. The study monitors patient disease activity and treatment responses using clinical assessments recorded in the database over two years. This observational approach allows researchers to track real-life experiences with avacopan and identify areas for future research and care improvements.

Early-access Avacopan in Real-world ANCA-associated Vasculitis